Atopiclair non steroid topical for Dermatitis

Atopiclair is a non-steroidal topical treatment indicated for the symptomatic relief of atopic, contact allergic and irritant dermatitis. It provides relief and long term management of the most common signs and symptoms such as itching, redness, burning and pain in adults and children.

Atopiclair is a steroid-free, paraben-free and scent-free emollient cream available in pharmacies, either by prescription or over the counter. Atopiclair is a class IIa medical device indicated in the treatment of mild to moderate atopic dermatitis in adults and children over the age of 6 months.

Atopiclair is a highly effective, clinically proven non-steroidal atopic dermatitis flare-remission treatmentAtopic dermatitis affects up to 20 percent1 of all young children.

Atopic dermatitis, or eczema as it is more commonly known, is a chronic inflammatory skin condition characterized by dry skin, intense itchiness, crusting, weeping and burning sensations. It is the most common chronic skin disease affecting up to 20% of young children, causing pain, sleep loss and preventing them from participating in normal activities such as swimming and playing with the family pet. Atopiclair offers effective relief and control of the symptoms associated with atopic dermatitis and has been proven safe and effective through randomized, double blind, controlled multi-center clinical trials including adults, children, and infants aged over 6 months. Atopiclair is specially formulated to reduce itching and restore the skin barrier.
Invida Group Private Limited today reaffirmed its commitment to patients in Asia Pacific by announcing the launch of a novel atopic dermatitis symptomatic treatment, Atopiclair™, which will be available to patients across Asia in second half of 2011. Atopiclair™, a non-steroidal atopic dermatitis flare-remission treatment, will potentially bring relief to young children and their families, whose lives are significantly impacted by the debilitating effects of the disease. The announcement was made at a press conference today, held in conjunction with the 22nd World Congress of Dermatology 2011 in Seoul, South Korea.
“Invida is committed to providing patients in Asia Pacific with medicines that will improve their lives,” said John A. Graham, Chief Executive Officer, Invida Group Private Limited. “Nearly one quarter of all dermatitis patients in the world are in Asia, so making Atopiclair™ available across the region is an important achievement, as it has proven to be such an effective treatment for the painful effects of atopic dermatitis in other parts of the world.
New treatment strategies are needed for atopic dermatitis because the currently available treatments carry labeling restrictions and their use is often limited due to concerns about side effects, particularly those caused by steroids

Atopiclair as a new, non-steroidal treatment option for atopic dermatitis patients in Asia. In a study published by Boguniewicz, et al, in the Journal of Pediatrics in 2008, Atopiclair™ was shown to be safe and effective as a monotherapy for the treatment of mild-to-moderate symptoms of atopic dermatitis, with children in the study experiencing complete or almost complete improvement in their symptoms within 22 days5.
At today’s press conference, Invida announced its planned launches of Atopiclair™ across numerous Asia Pacific markets. Invida Korea has a history of providing Korean physicians and patients with access to new therapies,” said Mark Brown, Invida Korea Country Manager. “We are very excited to add Atopiclair™ to our product portfolio in Korea and believe that Atopiclair™ will be a significant treatment to help patients and their families better manage the debilitating symptoms of atopic dermatitis.
Invida will soon also be introducing several other dermatology treatments in the region including Papulex™ for acne management, and Sebclair™ for seborrhoeic dermatitis.
The most widely recognized international dermatology gathering, the 22nd World Congress of Dermatology is being held from May 24-29 at the Coex Convention and Exhibition Center in Seoul, South Korea. Held every four years, the 2011 Congress is hosted by the International League of Dermatological Societies and organized by the Korean Dermatological Association.
About Invida Group Private Limited
Invida improves the lives of patients in Asia by commercializing differentiated pharmaceutical products of superior quality – the result of which will allow all Invida stakeholders to prosper. This is done through proven brand marketing and sales know-how, strong expertise across a number of key therapeutic categories and deep experience in all critical Asian markets. Comprehensive functional capabilities provide rapid market access delivered by our passionate team of professionals.
With more than 3,500 employees in 13 markets in Asia Pacific, Invida operates across the commercial value chain from regulatory approval and product launch to lifecycle management. Portfolio of proprietary healthcare brands as well as licensed products from emerging and large, multinational biopharmaceutical companies. Partnering is a critical component of Invida’s business model.

Atopiclair possesses a threefold action against atopic dermatitis:
it soothes itching rapidly,
it restores the skin barrier function, in particular by moisturizing the skin
it protects the skin and avoids the appearance of new episodes.
* Mild to moderate atopic dermatitis in adults and children aged 6 months and over
**Superficial skin layers

Atopiclair should be applied to affected areas, 3 times per day during inflammatory episodes.

Atopiclair was tested in monotherapy treatment of mild to moderate atopic dermatitis in adults, children and infants aged 6 months and over. It was well-tolerated during these trials.
Atopiclair contains neither paraben nor scent. Atopiclair can be used alone during remission phases, or in combination with dermocorticoids during inflammatory episodes. Ask your physician or pharmacist for advice

The New Perspective of Pathophysiology and Immunology Profile in Chronic Rhinosinusitis.

Widodo Judarwanto. Children Allergy Online Clinic, Jakarta Indonesia

Provided by


Yudhasmara Foundation htpp://

WORKING TOGETHER FOR STRONGER, SMARTER AND HEALTHIER CHILDREN BY EDUCATION, CLINICAL INTERVENTION, RESEARCH AND INFORMATION NETWORKING. Advancing of the future pediatric and future parenting to optimalized physical, mental and social health and well being for fetal, newborn, infant, children, adolescents and young adult



  • Dr Narulita Dewi SpKFR, Physical Medicine & Rehabilitation
  • Dr Widodo Judarwanto SpA, Pediatrician
  • Fisioterapis

Clinical and Editor in Chief :

Dr Widodo Judarwanto, pediatrician email :, Curiculum Vitae

Information on this web site is provided for informational purposes only and is not a substitute for professional medical advice. You should not use the information on this web site for diagnosing or treating a medical or health condition. You should carefully read all product packaging. If you have or suspect you have a medical problem, promptly contact your professional healthcare provider.

Copyright © 2012, Children Allergy Clinic Online Information Education Network. All rights reserved


Tinggalkan Balasan

Isikan data di bawah atau klik salah satu ikon untuk log in:


You are commenting using your account. Logout / Ubah )

Gambar Twitter

You are commenting using your Twitter account. Logout / Ubah )

Foto Facebook

You are commenting using your Facebook account. Logout / Ubah )

Foto Google+

You are commenting using your Google+ account. Logout / Ubah )

Connecting to %s